|
|
|
Ulcerative Colitis Clinical Trials, Diagnosis, and Treatment |
|
Thank you for your interest in clinical trials for Ulcerative Colitis.
Please click "Search" to find Ulcerative Colitis clinical trials and medical research studies or read below for information on Ulcerative Colitis diagnosis and treatment.
If you receive too many study listings you may enter your zip code to find the locations closest to you.
|
|
|
|
|
Results from Clinical Connection:
|
|
|
|
Your search returned 5 studies:
|
|
|
|
|
Results from other databases:
|
|
Your search returned over 250 results. The top 250 results are being displayed. Please use additional keywords or decrease the search distance. |
|
Your search returned 250 studies:
- A Study of the Safety and Effectiveness of CNTO 148 (Golimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (CR014176) - NCT00487539-
Conditions: Ulcerative Colitis Location: Milwaukee, WI
- A Study of the Safety and Effectiveness of CNTO 148 (Golimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (CR014179) - NCT00488631-
Conditions: Ulcerative Colitis Location: Milwaukee, WI
- A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis - NCT00694980-32610
Conditions: Ulcerative Colitis Location: Gainesville, FL
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-
Conditions: Ulcerative Colitis Location: Milwaukee, WI
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-06010
Conditions: Ulcerative Colitis Location: Bristol, CT
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-11021
Conditions: Ulcerative Colitis Location: Great Neck, NY
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-11733
Conditions: Ulcerative Colitis Location: Setauket, NY
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-17604
Conditions: Ulcerative Colitis Location: Lancaster, PA
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-21229
Conditions: Ulcerative Colitis Location: Balitmore, MD
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-21401
Conditions: Ulcerative Colitis Location: Annapolis, MD
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-22304
Conditions: Ulcerative Colitis Location: Alexandria, VA
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-27402
Conditions: Ulcerative Colitis Location: Greensboro, NC
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-30097
Conditions: Ulcerative Colitis Location: Atlanta, GA
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-30342
Conditions: Ulcerative Colitis Location: Atlanta, GA
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-32168
Conditions: Ulcerative Colitis Location: New Smyrna Beach, FL
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-32256
Conditions: Ulcerative Colitis Location: Jacksonville, FL
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-32605
Conditions: Ulcerative Colitis Location: Gainesville, FL
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-34684
Conditions: Ulcerative Colitis Location: Palm Harbor, FL
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-35209
Conditions: Ulcerative Colitis Location: Birmingham, AL
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-45219
Conditions: Ulcerative Colitis Location: Cincinnati, OH
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-48098
Conditions: Ulcerative Colitis Location: Troy, MI
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-52807
Conditions: Ulcerative Colitis Location: Davenport, IA
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-55905
Conditions: Ulcerative Colitis Location: Rochester, MN
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-60637
Conditions: Ulcerative Colitis Location: Chicago, IL
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-61265
Conditions: Ulcerative Colitis Location: Moline, IL
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-65265
Conditions: Ulcerative Colitis Location: Mexico, MO
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-77090
Conditions: Ulcerative Colitis Location: Houston, TX
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-78229
Conditions: Ulcerative Colitis Location: San Antonio, TX
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-84070
Conditions: Ulcerative Colitis Location: Sandy, UT
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-84094
Conditions: Ulcerative Colitis Location: Sandy, UT
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-90822
Conditions: Ulcerative Colitis Location: Long Beach, CA
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-92801
Conditions: Ulcerative Colitis Location: Anaheim, CA
- Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis - NCT01124149-92840
Conditions: Ulcerative Colitis Location: Garden Grove, CA
- An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease - NCT00790933-28621
Conditions: Ulcerative Colitis - Crohn's Disease Location: Elkin, NC
- An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease - NCT00790933-35233
Conditions: Ulcerative Colitis - Crohn's Disease Location: Birmingham, AL
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-01655
Conditions: Ulcerative Colitis Location: Worcester, MA
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-02114
Conditions: Ulcerative Colitis Location: Boston, MA
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-02903
Conditions: Ulcerative Colitis Location: Providence, RI
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-04102
Conditions: Ulcerative Colitis Location: Portland, ME
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-08330
Conditions: Ulcerative Colitis Location: Mays Landing, NJ
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-11040
Conditions: Ulcerative Colitis Location: New Hyde Park, NY
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-14222
Conditions: Ulcerative Colitis Location: Buffalo, NY
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-25701
Conditions: Ulcerative Colitis Location: Huntington, WV
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-32601
Conditions: Ulcerative Colitis Location: Gainesville, FL
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-33155
Conditions: Ulcerative Colitis Location: Miami, FL
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-35233
Conditions: Ulcerative Colitis Location: Birmingham, AL
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-37232
Conditions: Ulcerative Colitis Location: Nashville, TN
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-39202
Conditions: Ulcerative Colitis Location: Jackson, MS
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-40202
Conditions: Ulcerative Colitis Location: Louisville, KY
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-48075
Conditions: Ulcerative Colitis Location: Southfield, MI
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-60068
Conditions: Ulcerative Colitis Location: Park Ridge, IL
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-64108
Conditions: Ulcerative Colitis Location: Kansas City, MO
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-76104
Conditions: Ulcerative Colitis Location: Fort Worth, TX
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-78229
Conditions: Ulcerative Colitis Location: San Antonio, TX
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-85016
Conditions: Ulcerative Colitis Location: Phoenix, AZ
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-89109
Conditions: Ulcerative Colitis Location: Las Vegas, NV
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-92123
Conditions: Ulcerative Colitis Location: San Diego, CA
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-92354
Conditions: Ulcerative Colitis Location: Loma Linda, CA
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-94118
Conditions: Ulcerative Colitis Location: San Francisco, CA
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis - NCT01004185-94143
Conditions: Ulcerative Colitis Location: San Francisco, CA
- Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis - NCT00713310-
Conditions: Ulcerative Colitis Location: Huntington, WV
- Chromoendoscopy for Ulcerative Colitis Surveillance - NCT00274209-46202
Conditions: Ulcerative Colitis Location: Indianapolis, IN
- Clotrimazole Enemas for Pouchitis in Children and Adults - NCT00061282-02115
Conditions: Ulcerative Colitis - Pouchitis - Ileitis - Inflammatory Bowel Disease Location: Boston, MA
- Decisional Influences and Inflammatory Bowel Disease (IBD) Patients' Medication Use - NCT00968721-37232
Conditions: Crohn's Disease - Ulcerative Colitis Location: Nashville, TN
- Dose Escalation and Remission (DEAR) - NCT00652145-02904
Conditions: Ulcerative Colitis Location: Providence, RI
- Dose Escalation and Remission (DEAR) - NCT00652145-08053
Conditions: Ulcerative Colitis Location: Marlton, NJ
- Dose Escalation and Remission (DEAR) - NCT00652145-11733
Conditions: Ulcerative Colitis Location: Setauket, NY
- Dose Escalation and Remission (DEAR) - NCT00652145-19104
Conditions: Ulcerative Colitis Location: Philadelphia, PA
- Dose Escalation and Remission (DEAR) - NCT00652145-20707
Conditions: Ulcerative Colitis Location: Laurel, MD
- Dose Escalation and Remission (DEAR) - NCT00652145-20815
Conditions: Ulcerative Colitis Location: Chevy Chase, MD
- Dose Escalation and Remission (DEAR) - NCT00652145-21201
Conditions: Ulcerative Colitis Location: Baltimore, MD
- Dose Escalation and Remission (DEAR) - NCT00652145-30342
Conditions: Ulcerative Colitis Location: Atlanta, GA
- Dose Escalation and Remission (DEAR) - NCT00652145-55446
Conditions: Ulcerative Colitis Location: Plymouth, MN
- Effectiveness of Cognitive Behavioral Therapy in Reducing Depressive Symptoms in Physically Ill Youth - NCT00596869-02215
Conditions: Depression - Ulcerative Colitis Location: Boston, MA
- Effectiveness of Cognitive Behavioral Therapy in Reducing Depressive Symptoms in Physically Ill Youth - NCT00596869-15213
Conditions: Depression - Ulcerative Colitis Location: Pittsburgh, PA
- Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity - NCT01065571-60612
Conditions: Ulcerative Colitis Location: Chicago, IL
- Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity - NCT01065571-60637
Conditions: Ulcerative Colitis Location: Chicago, IL
- Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis - NCT00572585-06518
Conditions: Ulcerative Colitis Location: Hamden, CT
- Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis - NCT00572585-30263
Conditions: Ulcerative Colitis Location: Newnan, GA
- Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis - NCT00572585-36608
Conditions: Ulcerative Colitis Location: Mobile, AZ
- Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis - NCT00572585-48047
Conditions: Ulcerative Colitis Location: Troy, MI
- Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis - NCT00572585-48098
Conditions: Ulcerative Colitis Location: Chesterfield, MI
- Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis - NCT00572585-66606
Conditions: Ulcerative Colitis Location: Topeka, KS
- Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis - NCT00572585-70501
Conditions: Ulcerative Colitis Location: Layfayette, LA
- Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis - NCT00572585-73104
Conditions: Ulcerative Colitis Location: Oklahoma City, OK
- Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis - NCT00572585-85206
Conditions: Ulcerative Colitis Location: Mesa, AZ
- European Safety Registry in Ulcerative Colitis (Study P04808AM3) - NCT00705484-07033
Conditions: Ulcerative Colitis Location: Kenilworth, NJ
- Evaluation of Urinary Isoprostanes in the Assessment of Children With Inflammatory Bowel Disease - NCT00215020-02115
Conditions: Inflammatory Bowel Disease - Ulcerative Colitis - Crohn's Disease Location: Boston, MA
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-08053
Conditions: Ulcerative Colitis Location: Marlton, NJ
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-10016
Conditions: Ulcerative Colitis Location: New York, NY
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-11021
Conditions: Ulcerative Colitis Location: Great Neck, NY
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-14534
Conditions: Ulcerative Colitis Location: Pittsford, NY
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-16635
Conditions: Ulcerative Colitis Location: Duncansville, PA
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-18840
Conditions: Ulcerative Colitis Location: Sayre, PA
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-19464
Conditions: Ulcerative Colitis Location: Pottstown, PA
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-20636
Conditions: Ulcerative Colitis Location: Hollywood, MD
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-20678
Conditions: Ulcerative Colitis Location: Prince Frederick, MD
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-21229
Conditions: Ulcerative Colitis Location: Baltimore, MD
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-21401
Conditions: Ulcerative Colitis Location: Annapolis, MD
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-24073
Conditions: Ulcerative Colitis Location: Christianburg, VA
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-28078
Conditions: Ulcerative Colitis Location: Huntersville, NC
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-28304
Conditions: Ulcerative Colitis Location: Fayetteville, NC
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-28562
Conditions: Ulcerative Colitis Location: New Bern, NC
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-30312
Conditions: Ulcerative Colitis Location: Atlanta, GA
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-31904
Conditions: Ulcerative Colitis Location: Columbus, GA
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-32127
Conditions: Ulcerative Colitis Location: Port Orange, FL
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-32168
Conditions: Ulcerative Colitis Location: New Smyrna Beach, FL
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-32789
Conditions: Ulcerative Colitis Location: Winter Park, FL
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-33021
Conditions: Ulcerative Colitis Location: Hollywood, FL
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-33426
Conditions: Ulcerative Colitis Location: Boynton Beach, FL
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-33542
Conditions: Ulcerative Colitis Location: Zephyrhills, FL
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-33607
Conditions: Ulcerative Colitis Location: Tampa, FL
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-33613
Conditions: Ulcerative Colitis Location: Tampa, FL
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-35801
Conditions: Ulcerative Colitis Location: Huntsville, AL
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-45219
Conditions: Ulcerative Colitis Location: Cincinnati, OH
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-45440
Conditions: Ulcerative Colitis Location: Dayton, OH
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-48047
Conditions: Ulcerative Colitis Location: Chesterfield, MI
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-48098
Conditions: Ulcerative Colitis Location: Troy, MI
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-49519
Conditions: Ulcerative Colitis Location: Wyoming, MI
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-60201
Conditions: Ulcerative Colitis Location: Evanston, IL
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-70006
Conditions: Ulcerative Colitis Location: Metairie, LA
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-73099
Conditions: Ulcerative Colitis Location: Yukon, OK
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-75057
Conditions: Ulcerative Colitis Location: Lewisville, TX
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-75061
Conditions: Ulcerative Colitis Location: Irving, TX
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-75075
Conditions: Ulcerative Colitis Location: Plano, TX
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-77034
Conditions: Ulcerative Colitis Location: Houston, TX
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-77090A
Conditions: Ulcerative Colitis Location: Houston, TX
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-77090B
Conditions: Ulcerative Colitis Location: Houston, TX
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-77339
Conditions: Ulcerative Colitis Location: Kingwood, TX
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-77571
Conditions: Ulcerative Colitis Location: LaPort Texas, TX
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-78229
Conditions: Ulcerative Colitis Location: San Antonio, TX
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-78258
Conditions: Ulcerative Colitis Location: San Antonio, TX
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-78745
Conditions: Ulcerative Colitis Location: Austin, TX
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-80215
Conditions: Ulcerative Colitis Location: Lakewood, CO
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-84107
Conditions: Ulcerative Colitis Location: Salt Lake City, UT
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-85712
Conditions: Ulcerative Colitis Location: Tuscon, AZ
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-90045
Conditions: Ulcerative Colitis Location: Los Angeles, CA
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-90712
Conditions: Ulcerative Colitis Location: Lakewood, CA
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-92101
Conditions: Ulcerative Colitis Location: San Diego, CA
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-92262
Conditions: Ulcerative Colitis Location: Palm Springs, CA
- Extension Study of Budesonide MMX™ 6mg in Maintenance Of Remission In Patients With Ulcerative Colitis - NCT00801723-92801
Conditions: Ulcerative Colitis Location: Anaheim, CA
- General Surgical Outcomes Quality Improvement Database (GSOD)(SOCRATES) - NCT00622557-44106
Conditions: Colon Cancer - Diverticulitis - Colorectal Polyps - Crohn's Disease - Ulcerative Colitis - Rectal Cancer Location: Cleveland, OH
- Genetic Markers as Predictors of Phenotypes in Pediatric Onset Crohn's Disease - NCT00783575-53226
Conditions: Crohn's Disease - Ulcerative Colitis - Inflammatory Bowel Disease Location: Milwaukee, WI
- Immune Regulation in Ulcerative Colitis or Crohn's Disease - NCT00001184-20892
Conditions: Crohn's Disease - Inflammatory Bowel Disease - Ulcerative Colitis Location: Bethesda, MD
- Indigo Carmine Staining and Narrow Band Imaging (NBI) of Colonic Mucosa for Detection of Dysplasia in Ulcerative Colitis - NCT00961948-32224
Conditions: Ulcerative Colitis Location: Jacksonville, FL
- Johns Hopkins Crohn's Disease and Ulcerative Colitis Study - NCT01169207-21231
Conditions: Inflammatory Bowel Disease Location: Baltimore, MD
- Lactobacillus GG in Pediatric Ulcerative Colitis (UC) - NCT00895336-45229
Conditions: Ulcerative Colitis Location: Cincinnati, OH
- Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis - NCT00586599-46202
Conditions: Inflammatory Bowel Disease - Crohn's Disease - Ulcerative Colitis Location: Indianapolis, IN
- Managing Inflammatory Bowel Disease - NCT00679003-98105
Conditions: Inflammatory Bowel Disease - Crohn's Disease - Ulcerative Colitis Location: Seattle, WA
- Melatonin & Ulcerative Colitis - NCT00790478-
Conditions: Ulcerative Colitis Location: Atlanta, GA
- Melatonin & Ulcerative Colitis - NCT00790478-30322
Conditions: Ulcerative Colitis Location: Atlanta, GA
- Microparticles in Pediatric Inflammatory Disease - NCT00979485-46202
Conditions: Crohn's Disease - Ulcerative Colitis Location: Indianapolis, IN
- Mind/Body Medicine and IBD Flare-Up - NCT00568256-60612
Conditions: Ulcerative Colitis Location: Chicago, IL
- Partial Wave Spectroscopic Detection of Colon Cancer Risk - NCT01095432-60637
Conditions: Ulcerative Colitis - Colon Cancer Location: Chicago, IL
- Phase II Study of HMPL-004 in Patients With Ulcerative Colitis - NCT00659802-01001
Conditions: Ulcerative Colitis Location: Agawam, MA
- Pilot Study of Green Tea Extract (Polyphenon E®)in Ulcerative Colitis - NCT00718094-40202
Conditions: Mild to Moderately Active Ulcerative Colitis Location: Louisville, KY
- Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease - NCT00222378-33136
Conditions: Crohn's Disease - Ulcerative Colitis Location: Miami, FL
- Protein Metabolism in Newly Diagnosed Pediatric Inflammatory Bowel Disease - NCT00586352-46202
Conditions: Crohn's Disease - Ulcerative Colitis - Protein Metabolism Location: Indianapolis, IN
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis - NCT01164904-
Conditions: Ulcerative Colitis Location: Glendale, CA
- Study of Cimzia for the Treatment of Ulcerative Colitis - NCT01090154-19104
Conditions: Ulcerative Colitis Location: Philadelphia, PA
- Study of Cimzia for the Treatment of Ulcerative Colitis - NCT01090154-98195
Conditions: Ulcerative Colitis Location: Seattle, WA
- Study of Effects of L-Arginine in Colitis and Colon Cancer - NCT01091558-37232
Conditions: Ulcerative Colitis - Colon Cancer Location: Nashville, TN
- Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis - NCT01020708-73104
Conditions: Ulcerative Colitis Location: Oklahoma City, OK
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-02114
Conditions: Ulcerative Colitis Location: Boston, MA
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-02118
Conditions: Ulcerative Colitis Location: Boston, MA
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-03756
Conditions: Ulcerative Colitis Location: Lebanon, NH
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-06518
Conditions: Ulcerative Colitis Location: Hamden, CT
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-07960
Conditions: Ulcerative Colitis Location: Morristown, NJ
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-08360
Conditions: Ulcerative Colitis Location: Vineland, NJ
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-08903
Conditions: Ulcerative Colitis Location: New Brunswick, NJ
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-10021
Conditions: Ulcerative Colitis Location: New York, NY
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-10028
Conditions: Ulcerative Colitis Location: New York, NY
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-11021
Conditions: Ulcerative Colitis Location: Great Neck, NY
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-11358
Conditions: Ulcerative Colitis Location: Bayside, NY
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-11566
Conditions: Ulcerative Colitis Location: Merrick, NY
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-11733
Conditions: Ulcerative Colitis Location: Setauket, NY
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-11794
Conditions: Ulcerative Colitis Location: Stonybrook, NY
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-13210
Conditions: Ulcerative Colitis Location: Syracuse, NY
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-14225
Conditions: Ulcerative Colitis Location: Cheektowaga, NY
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-14534
Conditions: Ulcerative Colitis Location: Pittsford, NY
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-14642
Conditions: Ulcerative Colitis Location: Rochester, NY
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-15213
Conditions: Ulcerative Colitis Location: Pittsburgh, PA
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-20678
Conditions: Ulcerative Colitis Location: Prince Frederick, MD
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-20815
Conditions: Ulcerative Colitis Location: Chevy Chase, MD
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-21201
Conditions: Ulcerative Colitis Location: Baltimore, MD
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-22031
Conditions: Ulcerative Colitis Location: Fairfax, VA
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-22908
Conditions: Ulcerative Colitis Location: Charlottesville, VA
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-23249
Conditions: Ulcerative Colitis Location: Richmond, VA
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-23502
Conditions: Ulcerative Colitis Location: Norfolk, VA
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-27599
Conditions: Ulcerative Colitis Location: Chapel Hill, NC
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-28207
Conditions: Ulcerative Colitis Location: Charlotte, NC
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-28621
Conditions: Ulcerative Colitis Location: Elkin, NC
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-28655
Conditions: Ulcerative Colitis Location: Morganton, NC
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-29425
Conditions: Ulcerative Colitis Location: Charleston, SC
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-30033
Conditions: Ulcerative Colitis Location: Decatur, GA
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-30039
Conditions: Ulcerative Colitis Location: Snellville, GA
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-30263
Conditions: Ulcerative Colitis Location: Newnan, GA
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-30342
Conditions: Ulcerative Colitis Location: Atlanta, GA
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-31201
Conditions: Ulcerative Colitis Location: Macon, GA
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-31405
Conditions: Ulcerative Colitis Location: Savannah, GA
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-31904
Conditions: Ulcerative Colitis Location: Columbus, GA
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-32168
Conditions: Ulcerative Colitis Location: New Smyrna Beach, FL
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-32209
Conditions: Ulcerative Colitis Location: Jacksonville, FL
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-32223
Conditions: Ulcerative Colitis Location: Jacksonville, FL
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-32256
Conditions: Ulcerative Colitis Location: Jacksonville, FL
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-32608
Conditions: Ulcerative Colitis Location: Gainesville, FL
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-32789
Conditions: Ulcerative Colitis Location: Winter Park, FL
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-32806A
Conditions: Ulcerative Colitis Location: Orlando, FL
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-32806B
Conditions: Ulcerative Colitis Location: Orlando, FL
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-32901
Conditions: Ulcerative Colitis Location: Melbourne, FL
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-33136
Conditions: Ulcerative Colitis Location: Miami, FL
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-33606
Conditions: Ulcerative Colitis Location: Tampa, FL
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-33607
Conditions: Ulcerative Colitis Location: Tampa, FL
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-35233
Conditions: Ulcerative Colitis Location: Birmingham, AL
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-35234
Conditions: Ulcerative Colitis Location: Birmingham, AL
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-37232
Conditions: Ulcerative Colitis Location: Nashville, TN
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-38138
Conditions: Ulcerative Colitis Location: Germantown, TN
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-40202
Conditions: Ulcerative Colitis Location: Louisville, KY
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-40536
Conditions: Ulcerative Colitis Location: Lexington, KY
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-45219
Conditions: Ulcerative Colitis Location: Cincinnati, OH
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-45415
Conditions: Ulcerative Colitis Location: Dayton, OH
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-48098
Conditions: Ulcerative Colitis Location: Troy, MI
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-48124
Conditions: Ulcerative Colitis Location: Dearborn, MI
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-49519
Conditions: Ulcerative Colitis Location: Wyoming, MI
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-50325A
Conditions: Ulcerative Colitis Location: Clive, IA
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-50325B
Conditions: Ulcerative Colitis Location: Clive, IA
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-53215
Conditions: Ulcerative Colitis Location: Milwaukee, WI
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-53226
Conditions: Ulcerative Colitis Location: Milwaukee, WI
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-53717
Conditions: Ulcerative Colitis Location: Madison, WI
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-55486
Conditions: Ulcerative Colitis Location: Plymouth, MN
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-55905
Conditions: Ulcerative Colitis Location: Rochester, MN
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-61801
Conditions: Ulcerative Colitis Location: Urbana, IL
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-63110
Conditions: Ulcerative Colitis Location: St. Louis, MO
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-63128
Conditions: Ulcerative Colitis Location: St. Louis, MO
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-64108
Conditions: Ulcerative Colitis Location: Kansas City, MO
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-65265
Conditions: Ulcerative Colitis Location: Mexico, MO
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-66160
Conditions: Ulcerative Colitis Location: Kansas City, KS
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-66606
Conditions: Ulcerative Colitis Location: Topeka, KS
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-70809
Conditions: Ulcerative Colitis Location: Baton Rouge, LA
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-74104
Conditions: Ulcerative Colitis Location: Tulsa, OK
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-75701
Conditions: Ulcerative Colitis Location: Tyler, TX
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-77024
Conditions: Ulcerative Colitis Location: Houston, TX
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-77030
Conditions: Ulcerative Colitis Location: Houston, TX
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-77034
Conditions: Ulcerative Colitis Location: Houston, TX
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-77090
Conditions: Ulcerative Colitis Location: Houston, TX
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-77504
Conditions: Ulcerative Colitis Location: Pasadena, TX
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-78215
Conditions: Ulcerative Colitis Location: San Antonio, TX
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-78229
Conditions: Ulcerative Colitis Location: San Antonio, TX
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-78258
Conditions: Ulcerative Colitis Location: San Antonio, TX
- Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis - NCT00783718-78705
Conditions: Ulcerative Colitis Location: Austin, TX
|
|
|
|
|
Didn't find what you were looking for? Try these alternatives:
Become A Member: To be notified of upcoming clinical trials in your
area please create a free member account.
Browse Studies: If you would like to browse all featured clinical trials
please Browse Studies.
Message Board: Join the discussion in our Health
and Clinical Trials Message Board.
|
|
|